21世纪经济报道记者雷若馨深圳报道“国采”之后,卖药起家、位于深圳的康哲药业(0867.HK)在其创新转型之路上再进一步。11月27日,康哲药业公告,集团自主研发的创新药CMS-D005注射液获得国家药监局签发的药物临床试验批准通知书。同意集团在中国健康以及超重和肥胖成人受试者中开展评价CMS-D005安全性、耐受性及药代动力学和药效学特征的临床试验。目前,我国针对肥胖治疗适应症且获得NMPA批准...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.